FDA Approves Teva Pharmaceutical Industries Limited (TEVA) Leukemia Drug
10/26/2012 9:53:43 AM
Teva Pharmaceuticals | Jobs at Teva Pharmaceuticals
The U.S. Food and Drug Administration on Friday said it has approved a new leukemia treatment from Teva Pharmaceutical Industries Ltd to be sold under the brand name Synribo.
The drug, also known as omacetaxine mepesuccinate, is approved to treat a type of the blood and bone marrow cancer called chronic myelogenous leukemia, or CML, in patients whose cancer has progressed after treatment with at least two drugs from a class called tyrosine kinase inhibitors.